Parexel and Palantir to accelerate clinical data delivery and power clinical outcomes for patients

Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform to further power its clinical data platform

Merck initiates Phase 3 clinical trial of investigational oral KRAS G12C inhibitor MK-1084

For the first-line treatment of certain patients with metastatic non-small cell lung cancer

CuraTeQ Biologics announces the successful Phase 1 clinical study outcome of their BP11 product

Merck plans to conduct clinical trials of a novel investigational HPV vaccine for GARDASIL9

Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers

BlueRock Therapeutics Phase I clinical trial for Parkinson’s disease continues to show positive trends

Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months

Biomind Labs announces positive results of Phase 2 clinical trial of BMND08 for depression & anxiety in Alzheimer’s disease

Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg

UBE announces Phase I clinical trial for SSAO/VAP-1 licensed exclusively to Novo Nordisk

MASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver,

Ascletis announces dosing of the first patient in Phase III clinical trial of ASC40

This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40

Innovent Biologics, Xuanzhu collaborate on clinical trial for advanced solid tumors in China

Innovent will supply sintilimab for the collaborated clinical trial

Zydus receives USFDA approval USFDA to initiate Phase II clinical trial of ZYIL1 for Parkinson's disease

Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation